Date: 2013-05-14
Type of information: Production agreement
Compound: DNA vaccine candidate against HPV-induced malignancies
Company: Cobra Biologics (Sweden) Vaccibody (Norway)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: manufacturing
production
Action mechanism: Vaccibody’s technology exploits the interplay between tissue, antigen presenting cells (APC), T-cells and B-cells to develop targeted vaccines designed to induce stronger and longer lasting immune responses than traditional vaccines. The platform technology allows for the tailored development of not only enhanced prophylactic vaccines but also therapeutic vaccines against chronic infections and cancers.
Disease: HPV-induced malignancies such as precancerous lesions found in cervical cancer
Details: * On May 14, 2013, Cobra Biologics, a clinical and commercial manufacturer of biologics and pharmaceuticals and Vaccibody AS, a biotechnology company developing the next generation of vaccines against cancer and chronic infections, have announced an agreement to manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies, such as precancerous lesions found in cervical cancer.Cobra Biologics will apply its cost-effective platform process to deliver a programme of host strain generation, GMP cell banking, plasmid DNA production and clinical trials supply.
Financial terms:
Latest news:
